251
|
Arterbery AS, Osafo-Addo A, Avitzur Y, Ciarleglio M, Deng Y, Lobritto SJ, Martinez M, Hafler DA, Kleinewietfeld M, Ekong UD. Production of Proinflammatory Cytokines by Monocytes in Liver-Transplanted Recipients with De Novo Autoimmune Hepatitis Is Enhanced and Induces TH1-like Regulatory T Cells. THE JOURNAL OF IMMUNOLOGY 2016; 196:4040-51. [PMID: 27183637 DOI: 10.4049/jimmunol.1502276] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Accepted: 03/11/2016] [Indexed: 12/22/2022]
Abstract
A subset of human regulatory T cells (Tregs) can secrete IFN-γ or IL-17, and thus share features of TH1 or TH17 effector cells and lose suppressive function. The main factors driving this differentiation of Tregs toward a proinflammatory phenotype include IL-12 for TH1-like and IL-6 for TH17-type Tregs. In this study we show that Tregs of patients with de novo autoimmune hepatitis (dAIH) display increased frequencies of proinflammatory IFN-γ and IL-17 cytokines. Irrespective of a fully demethylated FOXP3 locus, Tregs of subjects with dAIH are functionally impaired. In line with the observed Treg phenotype, we detected the presence of two dominant cytokines (IL-12 and IL-6) clustering with CD68(+) monocyte/macrophage cells in livers of subjects with dAIH, and isolated monocytes of subjects with dAIH secrete high levels of proinflammatory IL-12 and IL-6, suggesting that this inflammatory milieu is key for functional impairment of Tregs. Importantly, the blockade of IFN-γ partially restores suppressive function of Tregs of subjects with dAIH, indicating that monocyte/macrophage-derived triggers might play a central role in Treg dysfunction and pathogenesis of dAIH.
Collapse
Affiliation(s)
- Adam S Arterbery
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06520
| | - Awo Osafo-Addo
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06520
| | - Yaron Avitzur
- Department of Pediatrics, University of Toronto, Toronto, Ontario MSG 1X8, Canada
| | - Maria Ciarleglio
- Department of Biostatistics, Yale School of Public Health, New Haven, CT 06520
| | - Yanhong Deng
- Yale Center for Analytic Sciences, Yale School of Public Health, New Haven, CT 06520
| | | | | | - David A Hafler
- Department of Neurology and Immunobiology, Yale University School of Medicine, New Haven, CT 06520
| | - Markus Kleinewietfeld
- Department of Clinical Pathobiochemistry, Medical Faculty Carl Gustav Carus, Dresden University of Technology, 01307 Dresden, Germany; and VIB Laboratory of Translational Immunomodulation, Biomedical Research Institute, Hasselt University, BE3590 Diepenbeek, Belgium
| | - Udeme D Ekong
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06520;
| |
Collapse
|
252
|
Wang S, Gao X, Shen G, Wang W, Li J, Zhao J, Wei YQ, Edwards CK. Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity. Sci Rep 2016; 6:24249. [PMID: 27075020 PMCID: PMC4831052 DOI: 10.1038/srep24249] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 03/18/2016] [Indexed: 02/05/2023] Open
Abstract
Regulatory T cells (Tregs) expand in peripheral lymphoid organs and can produce immunosuppressive cytokines to support tumor growth. IL-10 abrogation efficiently induces Treg formation but dampens tumoral neuropilin-1 (Nrp-1) Treg signaling, which simultaneously augments Th1 and Th17 immunity. These effects are associated with the plasticity and stability of Tregs and effector T cell functions that can limit tumorigenesis. Within the tumor microenvironment, there appears to be a “mutual antagonism” between immunoenhancement and immunosuppression mechanisms, eventually leading to decreased metastasis. In contrast, tumor progression is paralleled by a reduction in Nrp-1-producing Tregs controlled by the IL-10 and TGF-β1 levels. However, Th1, Th17 and Treg immunity is primarily regulated by IL-10 or Nrp-1 and not TGF-β1 except when combined with IL-10. These results emphasize the important implications for the therapeutic use of Tregs. The number of Treg cells must be maintained in a healthy and dynamic homeostatic range to prevent malignant diseases. Moreover, Treg-mediated immunosuppression can be limited by reducing tumor-derived Treg Nrp-1 levels.
Collapse
Affiliation(s)
- Shimin Wang
- Department of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China
| | - Xiang Gao
- Department of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China.,Institute of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China
| | - Guobo Shen
- Department of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China
| | - Wei Wang
- Department of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China
| | - Jingyu Li
- Department of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China
| | - Jingyi Zhao
- Department of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China
| | - Yu-Quan Wei
- Department of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China
| | - Carl K Edwards
- Department of Neurosurgery, State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, and West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China
| |
Collapse
|
253
|
|
254
|
Housley WJ, Fernandez SD, Vera K, Murikinati SR, Grutzendler J, Cuerdon N, Glick L, De Jager PL, Mitrovic M, Cotsapas C, Hafler DA. Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli. Sci Transl Med 2016; 7:291ra93. [PMID: 26062845 DOI: 10.1126/scitranslmed.aaa9223] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The transcription factor nuclear factor κB (NFκB) is a central regulator of inflammation, and genome-wide association studies in subjects with autoimmune disease have identified a number of variants within the NFκB signaling cascade. In addition, causal variant fine-mapping has demonstrated that autoimmune disease susceptibility variants for multiple sclerosis (MS) and ulcerative colitis are strongly enriched within binding sites for NFκB. We report that MS-associated variants proximal to NFκB1 and in an intron of TNFRSF1A (TNFR1) are associated with increased NFκB signaling after tumor necrosis factor-α (TNFα) stimulation. Both variants result in increased degradation of inhibitor of NFκB α (IκBα), a negative regulator of NFκB, and nuclear translocation of p65 NFκB. The variant proximal to NFκB1 controls signaling responses by altering the expression of NFκB itself, with the GG risk genotype expressing 20-fold more p50 NFκB and diminished expression of the negative regulators of the NFκB pathway: TNFα-induced protein 3 (TNFAIP3), B cell leukemia 3 (BCL3), and cellular inhibitor of apoptosis 1 (CIAP1). Finally, naïve CD4 T cells from patients with MS express enhanced activation of p65 NFκB. These results demonstrate that genetic variants associated with risk of developing MS alter NFκB signaling pathways, resulting in enhanced NFκB activation and greater responsiveness to inflammatory stimuli. As such, this suggests that rapid genetic screening for variants associated with NFκB signaling may identify individuals amenable to NFκB or cytokine blockade.
Collapse
Affiliation(s)
- William J Housley
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA
| | - Salvador D Fernandez
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA
| | - Kenneth Vera
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA
| | - Sasidhar R Murikinati
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA
| | - Jaime Grutzendler
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA
| | - Nicole Cuerdon
- Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
| | - Laura Glick
- Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
| | - Phillip L De Jager
- Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA
| | - Mitja Mitrovic
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA
| | - Chris Cotsapas
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA. Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA. Department of Genetics, Yale School of Medicine, New Haven, CT 06511, USA
| | - David A Hafler
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA. Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
| |
Collapse
|
255
|
Oral tolerance is inefficient in neonatal mice due to a physiological vitamin A deficiency. Mucosal Immunol 2016; 9:479-91. [PMID: 26530133 DOI: 10.1038/mi.2015.114] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Accepted: 09/30/2015] [Indexed: 02/04/2023]
Abstract
Increased risk of allergy during early life indicates deficient immune regulation in this period of life. To date, the cause for inefficient neonatal immune regulation has never been elucidated. We aimed to define the ontogeny of oral tolerance and to identify necessary conditions specific for this stage of life. Ovalbumin (OVA) was administered orally to mice through breast milk and efficiency of systemic tolerance to OVA was assessed in adulthood using a model of allergic airway inflammation. Oral tolerance induction was fully efficient starting third week of life. Inefficiency in neonates was a consequence of abnormal antigen transfer across the gut barrier and retinaldehyde dehydrogenase expression by mesenteric lymph node CD103(+) neonatal dendritic cells, resulting in inefficient T-cell activation. Neonates' serum retinol levels were three times lower than in adult mice, and vitamin A supplementation was sufficient to rescue neonatal defects and allow tolerance induction from birth. The establishment of oral tolerance required the differentiation of Th1 lymphocytes in both vitamin A-supplemented neonates and 3-week-old unsupplemented mice. This knowledge should guide the design of interventions for allergy prevention that are adapted to the neonatal stage of life such as vitamin A supplementation.
Collapse
|
256
|
Pacella I, Timperi E, Accapezzato D, Martire C, Labbadia G, Cavallari EN, D'Ettorre G, Calvo L, Rizzo F, Severa M, Coccia EM, Vullo V, Barnaba V, Piconese S. IFN-α promotes rapid human Treg contraction and late Th1-like Treg decrease. J Leukoc Biol 2016; 100:613-23. [PMID: 26921346 DOI: 10.1189/jlb.5a0415-140r] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 02/09/2016] [Indexed: 12/19/2022] Open
Abstract
Type I IFNs are pleiotropic cytokines that exert concerted activities in the development of antiviral responses. Regulatory T cells represent a physiologic checkpoint in the balance between immunity and tolerance, requiring fine and rapid controls. Here, we show that human regulatory T cells are particularly sensitive to the sequential effects of IFN-α. First, IFN-α exerts a rapid, antiproliferative and proapoptotic effect in vitro and in vivo, as early as after 2 d of pegylated IFN/ribavirin therapy in patients with chronic hepatitis C. Such activities result in the decline, at d 2, in circulating regulatory T cell frequency and specifically of the activated regulatory T cell subset. Later, IFN-based therapy restrains the fraction of regulatory T cells that can be polarized into IFN-γ-producing Th1-like regulatory T cells known to contribute to chronic immune activation in type 1 inflammation. Indeed, Th1-like regulatory T cell frequency significantly declines after 30 d of therapy in vivo in relation to the persistent decline of relevant IL-12 sources, namely, myeloid and 6-sulfo LacNAc-expressing dendritic cells. This event is recapitulated by experiments in vitro, providing evidence that it may be attributable to the inhibitory effect of IFN-α on IL-12-induced, Th1-like regulatory T cell polarization. In summary, our results suggest that IFN-α-driven, early regulatory T cell depletion contributes to the development of antiviral immunity, ultimately resulting in the resolution of type 1 inflammation.
Collapse
Affiliation(s)
- Ilenia Pacella
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy
| | - Eleonora Timperi
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy
| | - Daniele Accapezzato
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy
| | - Carmela Martire
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy
| | - Giancarlo Labbadia
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy
| | - Eugenio N Cavallari
- Department of Public Health and Infectious Diseases, Sapienza Università di Roma, Rome, Italy
| | - Gabriella D'Ettorre
- Department of Public Health and Infectious Diseases, Sapienza Università di Roma, Rome, Italy
| | - Ludovica Calvo
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy
| | - Fabiana Rizzo
- Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy; and
| | - Martina Severa
- Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy; and
| | - Eliana M Coccia
- Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy; and
| | - Vincenzo Vullo
- Department of Public Health and Infectious Diseases, Sapienza Università di Roma, Rome, Italy;
| | - Vincenzo Barnaba
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy; Istituto Pasteur-Fondazione Cenci Bolognetti, Rome, Italy
| | - Silvia Piconese
- Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy; Istituto Pasteur-Fondazione Cenci Bolognetti, Rome, Italy
| |
Collapse
|
257
|
Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin. Blood 2016; 127:1976-86. [PMID: 26903549 DOI: 10.1182/blood-2015-04-640300] [Citation(s) in RCA: 85] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Accepted: 02/09/2016] [Indexed: 12/22/2022] Open
Abstract
Self-tolerance and immune homeostasis are orchestrated by FOXP3(+)regulatory T cells (Tregs). Recent data have revealed that upon stimulation, Tregs may exhibit plasticity toward a proinflammatory phenotype, producing interleukin 17 (IL-17) and/or interferon γ (IFN-γ). Such deregulation of Tregs may contribute to the perpetuation of inflammatory processes, including graft-versus-host disease. Thus, it is important to identify immunomodulatory factors influencing Treg stability. Platelet-derived microparticles (PMPs) are involved in hemostasis and vascular health and have recently been shown to be intimately involved in (pathogenic) immune responses. Therefore, we investigated whether PMPs have the ability to affect Treg plasticity. PMPs were cocultured with healthy donor peripheral blood-derived Tregs that were stimulated with anti-CD3/CD28 monoclonal antibodies in the presence of IL-2, IL-15, and IL-1β. PMPs prevented the differentiation of peripheral blood-derived Tregs into IL-17- and IFN-γ-producing cells, even in the presence of the IL-17-driving proinflammatory cytokine IL-1β. The mechanism of action by which PMPs prevent Treg plasticity consisted of rapid and selective P-selectin-dependent binding of PMPs to a CCR6(+)HLA-DR(+)memory-like Treg subset and their ability to inhibit Treg proliferation, in part through CXCR3 engagement. The findings that ~8% of Tregs in the circulation of healthy individuals are CD41(+)P-selectin(+)and that distinct binding of patient plasma PMPs to Tregs was observed support in vivo relevance. These findings open the exciting possibility that PMPs actively regulate the immune response at sites of (vascular) inflammation, where they are known to accumulate and interact with leukocytes, consolidating the (vascular) healing process.
Collapse
|
258
|
Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol 2016; 16:149-63. [PMID: 26875830 DOI: 10.1038/nri.2015.18] [Citation(s) in RCA: 353] [Impact Index Per Article: 44.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
CD4(+) T cells differentiate and acquire distinct functions to combat specific pathogens but can also adapt their functions in response to changing circumstances. Although this phenotypic plasticity can be potentially deleterious, driving immune pathology, it also provides important benefits that have led to its evolutionary preservation. Here, we review CD4(+) T cell plasticity by examining the molecular mechanisms that regulate it - from the extracellular cues that initiate and drive cells towards varying phenotypes, to the cytosolic signalling cascades that decipher these cues and transmit them into the cell and to the nucleus, where these signals imprint specific gene expression programmes. By understanding how this functional flexibility is achieved, we may open doors to new therapeutic approaches that harness this property of T cells.
Collapse
|
259
|
Ellwardt E, Walsh JT, Kipnis J, Zipp F. Understanding the Role of T Cells in CNS Homeostasis. Trends Immunol 2016; 37:154-165. [DOI: 10.1016/j.it.2015.12.008] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Revised: 12/14/2015] [Accepted: 12/14/2015] [Indexed: 01/16/2023]
|
260
|
Yang L, Li B, Dang E, Jin L, Fan X, Wang G. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. J Dermatol Sci 2016; 81:85-92. [DOI: 10.1016/j.jdermsci.2015.11.007] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Revised: 10/28/2015] [Accepted: 11/13/2015] [Indexed: 12/18/2022]
|
261
|
Pedros C, Duguet F, Saoudi A, Chabod M. Disrupted regulatory T cell homeostasis in inflammatory bowel diseases. World J Gastroenterol 2016; 22:974-995. [PMID: 26811641 PMCID: PMC4716049 DOI: 10.3748/wjg.v22.i3.974] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 10/02/2015] [Accepted: 11/19/2015] [Indexed: 02/06/2023] Open
Abstract
In the gut, where billions of non-self-antigens from the food and the microbiota are present, the immune response must be tightly regulated to ensure both host protection against pathogenic microorganisms and the absence of immune-related pathologies. It has been well documented that regulatory T cells (Tregs) play a pivotal role in this context. Indeed, Tregs are able to prevent excessive inflammation, which can lead to the rupture of intestinal homeostasis observed in inflammatory bowel diseases (IBDs). Both the worldwide incidence and prevalence of such diseases have increased throughout the latter part of the 20th century. Therefore, it is crucial to understand how Tregs suppress the colitogenic immune cells to establish new treatments for patients suffering from IBDs. In this review, we will first summarize the results obtained in animal model studies that highlight the importance of Tregs in maintaining intestinal homeostasis and describe the specific suppressive mechanisms involved. Next, our current knowledge about Tregs contribution to human IBDs will be reviewed, as well as the current therapeutic perspective on using Tregs for clinical IBD treatment and the challenges that remain to be resolved to ensure both the safety and effectiveness of these therapies in targeting this critical immune-regulatory cell population.
Collapse
|
262
|
Hotson AN, Gopinath S, Nicolau M, Khasanova A, Finck R, Monack D, Nolan GP. Coordinate actions of innate immune responses oppose those of the adaptive immune system during Salmonella infection of mice. Sci Signal 2016; 9:ra4. [PMID: 26758212 DOI: 10.1126/scisignal.aaa9303] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The immune system enacts a coordinated response when faced with complex environmental and pathogenic perturbations. We used the heterogeneous responses of mice to persistent Salmonella infection to model system-wide coordination of the immune response to bacterial burden. We hypothesized that the variability in outcomes of bacterial growth and immune response across genetically identical mice could be used to identify immune elements that serve as integrators enabling co-regulation and interconnectedness of the innate and adaptive immune systems. Correlation analysis of immune response variation to Salmonella infection linked bacterial load with at least four discrete, interacting functional immune response "cassettes." One of these, the innate cassette, in the chronically infected mice included features of the innate immune system, systemic neutrophilia, and high serum concentrations of the proinflammatory cytokine interleukin-6. Compared with mice with a moderate bacterial load, mice with the highest bacterial burden exhibited high activity of this innate cassette, which was associated with a dampened activity of the adaptive T cell cassette-with fewer plasma cells and CD4(+) T helper 1 cells and increased numbers of regulatory T cells-and with a dampened activity of the cytokine signaling cassette. System-wide manipulation of neutrophil numbers revealed that neutrophils regulated signal transducer and activator of transcription (STAT) signaling in B cells during infection. Thus, a network-level approach demonstrated unappreciated interconnections that balanced innate and adaptive immune responses during the dynamic course of disease and identified signals associated with pathogen transmission status, as well as a regulatory role for neutrophils in cytokine signaling.
Collapse
Affiliation(s)
- Andrew N Hotson
- The Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Smita Gopinath
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Monica Nicolau
- The Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Anna Khasanova
- The Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Rachel Finck
- The Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Denise Monack
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Garry P Nolan
- The Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
| |
Collapse
|
263
|
Sela U, Park CG, Park A, Olds P, Wang S, Steinman RM, Fischetti VA. Dendritic Cells Induce a Subpopulation of IL-12Rβ2-Expressing Treg that Specifically Consumes IL-12 to Control Th1 Responses. PLoS One 2016; 11:e0146412. [PMID: 26745371 PMCID: PMC4706322 DOI: 10.1371/journal.pone.0146412] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 12/16/2015] [Indexed: 12/24/2022] Open
Abstract
Cytokines secreted from dendritic cells (DCs) play an important role in the regulation of T helper (Th) cell differentiation and activation into effector cells. Therefore, controlling cytokine secretion from DCs may potentially regulate Th differentiation/activation. DCs also induce de-novo generation of regulatory T cells (Treg) that modulate the immune response. In the current study we used the mixed leukocyte reaction (MLR) to investigate the effect of allospecific Treg on IL-12, TNFα and IL-6 secretion by DCs. Treg cells were found to markedly down-regulate IL-12 secretion from DCs following stimulation with TLR7/8 agonist. This down-regulation of IL-12 was neither due to a direct suppression of its production by the DCs nor a result of marked DC death. We found that IL-12 was rather actively consumed by Treg cells. IL-12 consumption was mediated by a subpopulation of IL-12Rβ2-expressing Treg cells and was dependent on MHC class-II expressed on dendritic cells. Furthermore, IL-12 consumption by Tregs increased their suppressive effect on T cell proliferation and Th1 activation. These results provide a new pathway of Th1 response regulation where IL-12 secreted by DCs is consumed by a sub-population of IL-12Rβ2-expressing Treg cells. Consumption of IL-12 by Tregs not only reduces the availability of IL-12 to Th effector cells but also enhances the Treg immunosuppressive effect. This DC-induced IL-12Rβ2-expressing Treg subpopulation may have a therapeutic advantage in suppressing Th1 mediated autoimmunity.
Collapse
Affiliation(s)
- Uri Sela
- Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Disease, The Rockefeller University, New York, NY, 10065, United States of America
- Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, NY, 10065, United States of America
- * E-mail:
| | - Chae Gyu Park
- Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Disease, The Rockefeller University, New York, NY, 10065, United States of America
- Laboratory of Immunology, Brain Korea 21 PLUS Project for Medical Science, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea
| | - Andrew Park
- Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Disease, The Rockefeller University, New York, NY, 10065, United States of America
| | - Peter Olds
- Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Disease, The Rockefeller University, New York, NY, 10065, United States of America
| | - Shu Wang
- Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, NY, 10065, United States of America
| | - Ralph M. Steinman
- Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Disease, The Rockefeller University, New York, NY, 10065, United States of America
| | - Vincent A. Fischetti
- Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, NY, 10065, United States of America
| |
Collapse
|
264
|
Dijke IE, Hoeppli RE, Ellis T, Pearcey J, Huang Q, McMurchy AN, Boer K, Peeters AMA, Aubert G, Larsen I, Ross DB, Rebeyka I, Campbell A, Baan CC, Levings MK, West LJ. Discarded Human Thymus Is a Novel Source of Stable and Long-Lived Therapeutic Regulatory T Cells. Am J Transplant 2016; 16:58-71. [PMID: 26414799 DOI: 10.1111/ajt.13456] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2015] [Revised: 06/19/2015] [Accepted: 07/14/2015] [Indexed: 01/25/2023]
Abstract
Regulatory T cell (Treg)-based therapy is a promising approach to treat many immune-mediated disorders such as autoimmune diseases, organ transplant rejection, and graft-versus-host disease (GVHD). Challenges to successful clinical implementation of adoptive Treg therapy include difficulties isolating homogeneous cell populations and developing expansion protocols that result in adequate numbers of cells that remain stable, even under inflammatory conditions. We investigated the potential of discarded human thymuses, routinely removed during pediatric cardiac surgery, to be used as a novel source of therapeutic Tregs. Here, we show that large numbers of FOXP3(+) Tregs can be isolated and expanded from a single thymus. Expanded thymic Tregs had stable FOXP3 expression and long telomeres, and suppressed proliferation and cytokine production of activated allogeneic T cells in vitro. Moreover, expanded thymic Tregs delayed development of xenogeneic GVHD in vivo more effectively than expanded Tregs isolated based on CD25 expression from peripheral blood. Importantly, in contrast to expanded blood Tregs, expanded thymic Tregs remained stable under inflammatory conditions. Our results demonstrate that discarded pediatric thymuses are an excellent source of therapeutic Tregs, having the potential to overcome limitations currently hindering the use of Tregs derived from peripheral or cord blood.
Collapse
Affiliation(s)
- I E Dijke
- Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.,Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada
| | - R E Hoeppli
- Department of Surgery, University of British Columbia, Vancouver, BC, Canada
| | - T Ellis
- Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.,Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada
| | - J Pearcey
- Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.,Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada
| | - Q Huang
- Department of Surgery, University of British Columbia, Vancouver, BC, Canada
| | - A N McMurchy
- Department of Surgery, University of British Columbia, Vancouver, BC, Canada
| | - K Boer
- Department of Internal Medicine, Erasmus MC Medical Center, Rotterdam, the Netherlands
| | - A M A Peeters
- Department of Internal Medicine, Erasmus MC Medical Center, Rotterdam, the Netherlands
| | - G Aubert
- Terry Fox Laboratory, British Columbia Cancer Research Centre, Vancouver, BC, Canada
| | - I Larsen
- Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.,Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada
| | - D B Ross
- Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada.,Department of Surgery, University of Alberta, Edmonton, AB, Canada
| | - I Rebeyka
- Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada.,Department of Surgery, University of Alberta, Edmonton, AB, Canada
| | - A Campbell
- Department of Surgery, University of British Columbia, Vancouver, BC, Canada
| | - C C Baan
- Department of Internal Medicine, Erasmus MC Medical Center, Rotterdam, the Netherlands
| | - M K Levings
- Department of Surgery, University of British Columbia, Vancouver, BC, Canada
| | - L J West
- Department of Pediatrics, University of Alberta, Edmonton, AB, Canada.,Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada.,Department of Surgery, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|
265
|
IL-10/IFNγ co-expressing CD4(+) T cells induced by IL-10 DC display a regulatory gene profile and downmodulate T cell responses. Clin Immunol 2015; 162:91-9. [PMID: 26639194 DOI: 10.1016/j.clim.2015.11.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 10/26/2015] [Accepted: 11/26/2015] [Indexed: 12/24/2022]
Abstract
Induced regulatory T cells (iTreg) are imperative for tolerance induction and spreading of infectious tolerance. Ex vivo generated tolerogenic dendritic cells (tDCs) have strong therapeutic potential to induce antigen-specific iTreg. We previously demonstrated that IL-10 tDC-primed T cells are very suppressive and produce IL-10. Here, we show that the majority of IL-10(+) T cells co-express IFNγ, giving rise to the question whether these cells are proinflammatory or regulatory. Whole genome gene expression analysis revealed a strong regulatory gene profile and a suppressed Th1 gene profile for IL-10/IFNγ co-expressing CD4(+) T cells. Protein analysis confirmed an extensive regulatory phenotype for IL-10(+)/IFNγ(+) T cells, with specific enhanced expression of GARP and PD-1. In line with these data, isolated IL-10(+)/IFNγ(+) T cells displayed potent suppressive capacity. Thus, IL-10/IFNγ co-expressing CD4(+) T cells induced by IL-10 tDC show dominance of immunomodulation over Th1-mediated immunoactivation and can contribute to induction or spreading of immunological tolerance.
Collapse
|
266
|
Oxidative stress in multiple sclerosis: Central and peripheral mode of action. Exp Neurol 2015; 277:58-67. [PMID: 26626971 PMCID: PMC7094520 DOI: 10.1016/j.expneurol.2015.11.010] [Citation(s) in RCA: 214] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Revised: 09/08/2015] [Accepted: 11/21/2015] [Indexed: 01/18/2023]
|
267
|
T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview. BIOMED RESEARCH INTERNATIONAL 2015; 2015:327470. [PMID: 26583100 PMCID: PMC4637008 DOI: 10.1155/2015/327470] [Citation(s) in RCA: 83] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Revised: 05/16/2015] [Accepted: 05/24/2015] [Indexed: 12/20/2022]
Abstract
In response to cytokine signalling and other factors, CD4-positive T lymphocytes differentiate into distinct populations that are characterized by the production of certain cytokines and are controlled by different master transcription factors. The spectrum of such populations, which was initially limited to Th1 and Th2 subsets, is currently broadened to include Th17 and Treg subsets, as well as a number of less studied subtypes, such as Tfh, Th9, and Th22. Although these subsets appear to be relatively stable, certain plasticity exists that allows for transition between the subsets and formation of hybrid transition forms. This provides the immune system flexibility needed for adequate response to pathogens but, at the same time, can play a role in the pathogenic processes in cases of deregulation. In this review, we will discuss the properties of T lymphocyte subsets and their plasticity, as well as its implications for cancer and autoimmune diseases.
Collapse
|
268
|
Hernandez AL, Kitz A, Wu C, Lowther DE, Rodriguez DM, Vudattu N, Deng S, Herold KC, Kuchroo VK, Kleinewietfeld M, Hafler DA. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J Clin Invest 2015; 125:4212-22. [PMID: 26524592 DOI: 10.1172/jci81151] [Citation(s) in RCA: 244] [Impact Index Per Article: 27.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Accepted: 08/20/2015] [Indexed: 12/12/2022] Open
Abstract
FOXP3+ Tregs are central for the maintenance of self-tolerance and can be defective in autoimmunity. In multiple sclerosis and type-1 diabetes, dysfunctional self-tolerance is partially mediated by a population of IFNγ-secreting Tregs. It was previously reported that increased NaCl concentrations promote the induction of proinflammatory Th17 cells and that high-salt diets exacerbate experimental models of autoimmunity. Here, we have shown that increasing NaCl, either in vitro or in murine models via diet, markedly impairs Treg function. NaCl increased IFNγ secretion in Tregs, and reducing IFNγ - either by neutralization with anti-IFNγ antibodies or shRNA-mediated knockdown - restored suppressive activity in Tregs. The heightened IFNγ secretion and loss of Treg function were mediated by the serum/glucocorticoid-regulated kinase (SGK1). A high-salt diet also impaired human Treg function and was associated with the induction of IFNγ-secreting Tregs in a xenogeneic graft-versus-host disease model and in adoptive transfer models of experimental colitis. Our results demonstrate a putative role for an environmental factor that promotes autoimmunity by inducing proinflammatory responses in CD4 effector cells and Treg pathways.
Collapse
MESH Headings
- Adoptive Transfer
- Animals
- Antibodies, Neutralizing/immunology
- Autoimmunity/drug effects
- CD4-Positive T-Lymphocytes/immunology
- Cells, Cultured
- Coculture Techniques
- Colitis/immunology
- Cytokines/biosynthesis
- Cytokines/genetics
- Forkhead Transcription Factors/analysis
- Forkhead Transcription Factors/genetics
- Gene Expression Profiling
- Genes, Reporter
- Graft vs Host Disease/immunology
- Heterografts
- Humans
- Immediate-Early Proteins/physiology
- Inflammation
- Interferon-gamma/genetics
- Interferon-gamma/metabolism
- Interferon-gamma/pharmacology
- Leukocytes, Mononuclear/transplantation
- Male
- Mice
- Protein Serine-Threonine Kinases/physiology
- RNA Interference
- RNA, Small Interfering/genetics
- Sodium Chloride/pharmacology
- Sodium Chloride, Dietary/adverse effects
- Sodium Chloride, Dietary/pharmacology
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/metabolism
Collapse
|
269
|
O’Connor RA, Anderton SM. Inflammation-associated genes: risks and benefits to Foxp3+ regulatory T-cell function. Immunology 2015; 146:194-205. [PMID: 26190495 PMCID: PMC4582961 DOI: 10.1111/imm.12507] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Revised: 06/30/2015] [Accepted: 07/02/2015] [Indexed: 01/10/2023] Open
Abstract
Foxp3(+) regulatory T (Treg) cells prevent the development of autoimmunity and immunopathology, as well as maintaining homeostasis and tolerance to commensal microorganisms. The suppressive activity of Treg cells is their defining characteristic, generating great interest in their therapeutic potential. However, suppressive and effector functions are not entirely exclusive. Considerable evidence points to the ability of supposedly anti-inflammatory Foxp3-expressing Treg cells to also express transcription factors that have been characterized as cardinal drivers of T effector cell function. We will consider the mounting evidence that Treg cells can function in non-suppressive capacities and review the impetus for this functional change, its relevance to developing immune and autoimmune responses and its significance to the development of Treg-based therapies.
Collapse
Affiliation(s)
- Richard A O’Connor
- MRC Centre for Inflammation Research, Centre for Multiple Sclerosis Research and Centre for Immunity Infection and Evolution, University of EdinburghEdinburgh, UK
| | - Stephen M Anderton
- MRC Centre for Inflammation Research, Centre for Multiple Sclerosis Research and Centre for Immunity Infection and Evolution, University of EdinburghEdinburgh, UK
| |
Collapse
|
270
|
Hall BM, Tran GT, Robinson CM, Hodgkinson SJ. Induction of antigen specific CD4+CD25+Foxp3+T regulatory cells from naïve natural thymic derived T regulatory cells. Int Immunopharmacol 2015; 28:875-86. [DOI: 10.1016/j.intimp.2015.03.049] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2015] [Accepted: 03/28/2015] [Indexed: 12/14/2022]
|
271
|
Arellano G, Ottum PA, Reyes LI, Burgos PI, Naves R. Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Front Immunol 2015; 6:492. [PMID: 26483787 PMCID: PMC4586507 DOI: 10.3389/fimmu.2015.00492] [Citation(s) in RCA: 106] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2015] [Accepted: 09/09/2015] [Indexed: 12/21/2022] Open
Abstract
The role of interferon (IFN)-γ in multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), has remained as an enigmatic paradox for more than 30 years. Several studies attribute this cytokine a prominent proinflammatory and pathogenic function in these pathologies. However, accumulating evidence shows that IFN-γ also plays a protective role inducing regulatory cell activity and modulating the effector T cell response. Several innate and adaptive immune cells also develop opposite functions strongly associated with the production of IFN-γ in EAE. Even the suppressive activity of different types of regulatory cells is dependent on IFN-γ. Interestingly, recent data supports a stage-specific participation of IFN-γ in EAE providing a plausible explanation for previous conflicting results. In this review, we will summarize and discuss such literature, emphasizing the protective role of IFN-γ on immune cells. These findings are fundamental to understand the complex role of IFN-γ in the pathogenesis of these diseases and can provide basis for potential stage-specific therapy for MS targeting IFN-γ-signaling or IFN-γ-producing immune cells.
Collapse
Affiliation(s)
- Gabriel Arellano
- Immunology Program, Biomedical Sciences Institute, School of Medicine, Universidad de Chile , Santiago , Chile
| | - Payton A Ottum
- Immunology Program, Biomedical Sciences Institute, School of Medicine, Universidad de Chile , Santiago , Chile
| | - Lilian I Reyes
- Faculty of Science, Universidad San Sebastián , Santiago , Chile
| | - Paula I Burgos
- Department of Clinical Immunology and Rheumatology, School of Medicine, Pontificia Universidad Católica de Chile , Santiago , Chile
| | - Rodrigo Naves
- Immunology Program, Biomedical Sciences Institute, School of Medicine, Universidad de Chile , Santiago , Chile
| |
Collapse
|
272
|
Yamada A, Ushio A, Arakaki R, Tsunematsu T, Kudo Y, Hayashi Y, Ishimaru N. Impaired expansion of regulatory T cells in a neonatal thymectomy-induced autoimmune mouse model. THE AMERICAN JOURNAL OF PATHOLOGY 2015; 185:2886-97. [PMID: 26343329 DOI: 10.1016/j.ajpath.2015.07.007] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2015] [Revised: 06/17/2015] [Accepted: 07/28/2015] [Indexed: 11/16/2022]
Abstract
Neonatal thymectomy in certain mouse strains is known to induce organ-specific autoimmunity due to impaired functions of T cells, including Foxp3(+) regulatory T (Treg) cells in the thymus. The precise mechanism underlying the induction of autoimmunity by neonatal thymectomy remains unclear. One possibility is that depletion of Treg cells breaks down peripheral tolerance. We examined the functions of Treg cells by using a murine Sjögren syndrome model of NFS/sld mice that underwent neonatal thymectomy. The ratio of Treg cells to effector memory phenotype T cells in thymectomy mice was significantly lower than that of nonthymectomy mice. In addition, in vitro induction of peripherally induced Treg cells by transforming growth factor-β (TGF-β) using naive T cells from Sjögren syndrome model mice was severely impaired. The mRNA expression of TGF-β receptor I and II and Smad3 and -4 in the TGF-β-induced signal transduction pathway of Treg cells in this Sjögren syndrome model were lower than those of control mice. In addition, Treg cells in this Sjögren syndrome model exhibited an interferon-γ-producing Th1-like phenotype that resembled effector T cells. In conclusion, these results suggest that abnormal expansion and differentiation of Treg cells and inflammatory cytokines produced by Treg cells contribute to the development of autoimmunity.
Collapse
Affiliation(s)
- Akiko Yamada
- Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Aya Ushio
- Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Rieko Arakaki
- Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Takaaki Tsunematsu
- Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Yasusei Kudo
- Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Yoshio Hayashi
- Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Naozumi Ishimaru
- Department of Oral Molecular Pathology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
| |
Collapse
|
273
|
Braza F, Durand M, Degauque N, Brouard S. Regulatory T Cells in Kidney Transplantation: New Directions? Am J Transplant 2015; 15:2288-300. [PMID: 26234373 DOI: 10.1111/ajt.13395] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Revised: 05/03/2015] [Accepted: 05/24/2015] [Indexed: 01/25/2023]
Abstract
The contribution of regulatory T cells in the maintenance of kidney graft survival is of major interest. Although many experimental models suggest a role in the induction of graft tolerance, reproducing these findings in clinic is less clear. While modulation of the regulatory T cell response is a promising therapeutic concept in transplantation, a better understanding of function, phenotype and biology is needed to be able to optimally exploit these cells in order to induce graft tolerance. With this in mind, we review here the current understanding of the phenotypic-functional delineation of Tregs and how Tregs can contribute to graft survival. We highlight their potential role in long-term graft survival and kidney operational tolerance. We also discuss the mechanisms needed for the molecular development of regulatory T cells: A combination of FOXP3 molecular partners, epigenetic, metabolic, and posttranslational modifications are necessary to generate well-functioning regulatory T cells and maintain their core identify. We discuss how an improved understanding of these mechanisms will permit the identification of new potent therapeutic strategies to improve kidney graft survival.
Collapse
Affiliation(s)
- F Braza
- Université, de Nantes, Faculté de Médecine, Nantes, F-44035, France.,INSERM, UMR 1064, Nantes, F-44093, France.,CHU de Nantes, ITUN, Nantes, F-44093, France
| | - M Durand
- Université, de Nantes, Faculté de Médecine, Nantes, F-44035, France.,INSERM, UMR 1064, Nantes, F-44093, France.,CHU de Nantes, ITUN, Nantes, F-44093, France
| | - N Degauque
- INSERM, UMR 1064, Nantes, F-44093, France.,CHU de Nantes, ITUN, Nantes, F-44093, France
| | - S Brouard
- INSERM, UMR 1064, Nantes, F-44093, France.,CHU de Nantes, ITUN, Nantes, F-44093, France
| |
Collapse
|
274
|
Daniel V, Trojan K, Adamek M, Opelz G. IFNγ+ Treg in-vivo and in-vitro represent both activated nTreg and peripherally induced aTreg and remain phenotypically stable in-vitro after removal of the stimulus. BMC Immunol 2015; 16:45. [PMID: 26268522 PMCID: PMC4535851 DOI: 10.1186/s12865-015-0111-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 07/31/2015] [Indexed: 12/30/2022] Open
Abstract
Background IFNγ-producing CD4+CD25+Foxp3+CD127- Treg represent the first line of Treg during an immune response. In the present study we determined whether IFNγ+ Treg in-vivo and in-vitro are Helios-positive representing activated natural (nTreg) or Helios-negative representing adaptive Treg (aTreg) and whether they originate from CD4+CD25+ and/or CD4+CD25- PBL. Furtheron, we investigated whether they are inducible by recombinant IFNγ (rIFNγ) as a single stimulus, decrease in-vitro after elimination of the stimulus, and have a demethylated Foxp3 Treg-specific demethylated region (TSDR) which is associated with stable Foxp3 expression. Method Subsets of IFNγ+ Treg were determined in peripheral blood of healthy controls using eight-color flow cytometry and were further investigated in-vitro. Foxp3 TSDR methylation status was determined using bisulphite polymerase chain reaction (PCR) and high resolution melt (HRM) analysis. Results Nearly all Treg in the peripheral blood were Helios+IFNγ- (1.9 ± 1.1/μl) and only few were Helios+IFNγ+ or Helios-IFNγ+ Treg (both 0.1 ± 0.1/μl). Enriched IFNγ+ Treg subsets showed in part strong Foxp3 TSDR demethylation. In-vitro, rIFNγ was unable to induce Treg. CD4+CD25+ enriched PBL stimulated with PMA/Ionomycin in the presence of rIFNγ were rather resistant to the effect of rIFNγ, in contrast to CD4+CD25- enriched PBL which showed increasing total Treg with Helios+ Treg switching from IFNγ- to IFNγ+ and increasing Helios-IFNγ+ Treg. The data indicate that rIFNγ, in combination with a polyclonal stimulus, activates nTreg and induces aTreg. When phorbol 12-myristate 13-acetate (PMA)/Ionomycin was washed out from the cell culture after 6 h stimulation, Treg induction continued for at least 96 h of cell culture, contradicting the hypothesis that removal of the stimulus results in significant decrease of IFNγ- and IFNγ+ CD4+CD25+Foxp3+CD127- Treg due to loss of Foxp3 expression. Conclusions IFNγ+Helios- aTreg as well as IFNγ+Helios+ nTreg are detectable in the blood of healthy individuals, show in part strong Foxp3 TSDR demethylation and are inducible in-vitro. The present data provide further insight concerning the in-vivo and in-vitro characteristics of IFNγ+ Treg and help to understand their role in immunoregulation. Alloantigen-specific demethylated IFNγ+Helios+ nTreg might represent a suitable marker for monitoring graft-specific immunosuppression in renal transplant recipients.
Collapse
Affiliation(s)
- Volker Daniel
- Department of Transplantation-Immunology, Institute of Immunology, University Hospital Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg, Germany.
| | - Karina Trojan
- Department of Transplantation-Immunology, Institute of Immunology, University Hospital Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg, Germany.
| | - Martina Adamek
- Department of Transplantation-Immunology, Institute of Immunology, University Hospital Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg, Germany.
| | - Gerhard Opelz
- Department of Transplantation-Immunology, Institute of Immunology, University Hospital Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg, Germany.
| |
Collapse
|
275
|
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015; 15:545-58. [PMID: 26250739 DOI: 10.1038/nri3871] [Citation(s) in RCA: 1432] [Impact Index Per Article: 159.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Two decades of clinical experience with immunomodulatory treatments for multiple sclerosis point to distinct immunological pathways that drive disease relapses and progression. In light of this, we discuss our current understanding of multiple sclerosis immunopathology, evaluate long-standing hypotheses regarding the role of the immune system in the disease and delineate key questions that are still unanswered. Recent and anticipated advances in the field of immunology, and the increasing recognition of inflammation as an important component of neurodegeneration, are shaping our conceptualization of disease pathophysiology, and we explore the potential implications for improved healthcare provision to patients in the future.
Collapse
Affiliation(s)
- Calliope A Dendrou
- Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
| | - Lars Fugger
- Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.,Clinical Institute, Aarhus University Hospital, DK-8200 Aarhus, Denmark
| | - Manuel A Friese
- Institut für Neuroimmunologie und Multiple Sklerose, Zentrum für Molekulare Neurobiologie Hamburg, Universitätsklinikum Hamburg-Eppendorf, 20246 Hamburg, Germany
| |
Collapse
|
276
|
Pianta A, Drouin EE, Crowley JT, Arvikar S, Strle K, Costello CE, Steere AC. Annexin A2 is a target of autoimmune T and B cell responses associated with synovial fibroblast proliferation in patients with antibiotic-refractory Lyme arthritis. Clin Immunol 2015; 160:336-41. [PMID: 26187145 DOI: 10.1016/j.clim.2015.07.005] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 07/06/2015] [Indexed: 01/12/2023]
Abstract
In this study, autoantibody responses to annexin A2 were found in 11-15% of 278 patients with Lyme disease, including in those with erythema migrans (EM), an early sign of the illness, and in those with antibiotic-responsive or antibiotic-refractory Lyme arthritis (LA), a late disease manifestation. In contrast, robust T cell reactivity to annexin A2 peptides was found only in patients with responsive or refractory LA. In LA patients, annexin A2 protein levels, which were higher in the refractory group, correlated with annexin A2 antibody levels in sera and synovial fluid. In addition, in patients with antibiotic-refractory LA who had anti-annexin A2 antibodies, synovial tissue had intense staining for annexin A2 protein, greater synovial fibroblast proliferation and more tissue fibrosis. Thus, a subset of LA patients had T and B cell responses to annexin A2, and in the refractory group, annexin A2 autoantibodies were associated with specific pathologic findings.
Collapse
Affiliation(s)
- Annalisa Pianta
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, United States.
| | - Elise E Drouin
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, United States
| | - Jameson T Crowley
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, United States
| | - Sheila Arvikar
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, United States
| | - Klemen Strle
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, United States
| | - Catherine E Costello
- Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, United States
| | - Allen C Steere
- Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, United States
| |
Collapse
|
277
|
Procaccini C, De Rosa V, Pucino V, Formisano L, Matarese G. Animal models of Multiple Sclerosis. Eur J Pharmacol 2015; 759:182-91. [PMID: 25823807 PMCID: PMC7094661 DOI: 10.1016/j.ejphar.2015.03.042] [Citation(s) in RCA: 216] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Revised: 01/30/2015] [Accepted: 03/12/2015] [Indexed: 12/26/2022]
Abstract
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) which involves a complex interaction between immune system and neural cells. Animal modeling has been critical for addressing MS pathogenesis. The three most characterized animal models of MS are (1) the experimental autoimmune/allergic encephalomyelitis (EAE); (2) the virally-induced chronic demyelinating disease, known as Theiler׳s murine encephalomyelitis virus (TMEV) infection and (3) the toxin-induced demyelination. All these models, in a complementary way, have allowed to reach a good knowledge of the pathogenesis of MS. Specifically, EAE is the model which better reflects the autoimmune pathogenesis of MS and is extremely useful to study potential experimental treatments. Furthermore, both TMEV and toxin-induced demyelination models are suitable for characterizing the role of the axonal injury/repair and the remyelination process in MS. In conclusion, animal models, despite their limitations, remain the most useful instrument for implementing the study of MS.
Collapse
MESH Headings
- Animals
- Cardiovirus Infections/pathology
- Cardiovirus Infections/virology
- Disease Models, Animal
- Encephalomyelitis, Autoimmune, Experimental/etiology
- Encephalomyelitis, Autoimmune, Experimental/genetics
- Encephalomyelitis, Autoimmune, Experimental/immunology
- Encephalomyelitis, Autoimmune, Experimental/pathology
- Humans
- Mice
- Mice, Transgenic
- Multiple Sclerosis/etiology
- Multiple Sclerosis/genetics
- Multiple Sclerosis/immunology
- Multiple Sclerosis/pathology
- Theilovirus/pathogenicity
Collapse
Affiliation(s)
- Claudio Procaccini
- Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR) c/o Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", 80131 Napoli, Italy
| | - Veronica De Rosa
- Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR) c/o Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli "Federico II", 80131 Napoli, Italy; Unità di NeuroImmunologia, IRCCS Fondazione Santa Lucia, 00143 Roma, Italy
| | - Valentina Pucino
- Dipartimento di Scienze Mediche Traslazionali, Università di Napoli Federico II, 80131 Napoli, Italy
| | - Luigi Formisano
- Divisione di Farmacologia, Dipartimento di Scienze e Tecnologie, Università degli Studi del Sannio, 82100 Benevento, Italy
| | - Giuseppe Matarese
- Dipartimento di Medicina e Chirurgia, Università degli Studi di Salerno, Baronissi Campus, 84081 Baronissi, Salerno, Italy; IRCCS Multimedica, 20138 Milano, Italy.
| |
Collapse
|
278
|
Pandiyan P, Zhu J. Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells. Cytokine 2015; 76:13-24. [PMID: 26165923 DOI: 10.1016/j.cyto.2015.07.005] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Revised: 06/24/2015] [Accepted: 07/03/2015] [Indexed: 12/12/2022]
Abstract
CD4(+)CD25(+)Foxp3(+) regulatory cells (Tregs) are a special lineage of cells central in the maintenance of immune homeostasis, and are targeted for human immunotherapy. They are conventionally associated with the production of classical anti-inflammatory cytokines such as IL-10, TGF-β and IL-35, consistent to their anti-inflammatory functions. However, emerging evidence show that they also express effector cytokines such as IFN-γ and IL-17A under inflammatory conditions. While some studies reveal that these pro-inflammatory cytokine producing Foxp3(+) regulatory cells retain their suppressive ability, others believe that these cells are dys-regulated and are associated with perpetuation of immunopathology. Therefore the development of these cells may challenge the efficacy of human Treg therapy. Mechanistically, toll-like receptor (TLR) ligands and the pro-inflammatory cytokine milieu have been shown to play important roles in the induction of effector cytokines in Tregs. Here we review the mechanisms of development and the possible functions of pro-inflammatory cytokine producing Foxp3+ Tregs.
Collapse
Affiliation(s)
- Pushpa Pandiyan
- Department of Biological Sciences, School of Dental Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
| | - Jinfang Zhu
- Molecular and Cellular Immunoregulation Unit, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
279
|
Verhagen J, Wegner A, Wraith DC. Extra-thymically induced T regulatory cell subsets: the optimal target for antigen-specific immunotherapy. Immunology 2015; 145:171-81. [PMID: 25716063 DOI: 10.1111/imm.12458] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 02/20/2015] [Accepted: 02/21/2015] [Indexed: 12/13/2022] Open
Abstract
Antigen-specific immunotherapy aims to selectively restore tolerance to innocuous antigens in cases of autoimmune or allergic disease, without the need for general immune suppression. Although the principle of antigen-specific immunotherapy was discovered more than a century ago, its clinical application to date is limited, particularly in the control of autoimmunity. This has resulted mainly from a lack of in-depth understanding of the underlying mechanism. More recently, the differentiation of extra-thymically induced T regulatory (Treg) cell subsets has been shown to be instrumental in peripheral tolerance induction. Two main types of inducible Treg cells, interleukin-10-secreting or Foxp3(+) , have now been described, each with distinct characteristics and methods of therapeutic induction. It is crucial, therefore, to identify the suitability of either subset in the control of specific immune disorders. This review explores their natural function, the known mechanisms of therapeutic differentiation of either subset as well as their in vivo functionality and discusses new developments that may aid their use in antigen-specific immunotherapy, with a focus on autoimmune disease.
Collapse
Affiliation(s)
- Johan Verhagen
- School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK
| | | | | |
Collapse
|
280
|
Khare A, Chakraborty K, Raundhal M, Ray P, Ray A. Cutting Edge: Dual Function of PPARγ in CD11c+ Cells Ensures Immune Tolerance in the Airways. THE JOURNAL OF IMMUNOLOGY 2015; 195:431-5. [PMID: 26062999 DOI: 10.4049/jimmunol.1500474] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2015] [Accepted: 05/17/2015] [Indexed: 01/15/2023]
Abstract
The respiratory tract maintains immune homeostasis despite constant provocation by environmental Ags. Failure to induce tolerogenic responses to allergens incites allergic inflammation. Despite the understanding that APCs have a crucial role in maintaining immune tolerance, the underlying mechanisms are poorly understood. Using mice with a conditional deletion of peroxisome proliferator-activated receptor γ (PPARγ) in CD11c(+) cells, we show that PPARγ performs two critical functions in CD11c(+) cells to induce tolerance, thereby preserving immune homeostasis. First, PPARγ was crucial for the induction of retinaldehyde dehydrogenase (aldh1a2) selectively in CD103(+) dendritic cells, which we recently showed promotes Foxp3 expression in naive CD4(+) T cells. Second, in all CD11c(+) cells, PPARγ was required to suppress expression of the Th17-skewing cytokines IL-6 and IL-23p19. Also, lack of PPARγ in CD11c(+) cells induced p38 MAPK activity, which was recently linked to Th17 development. Thus, PPARγ favors immune tolerance by promoting regulatory T cell generation and blocking Th17 differentiation.
Collapse
Affiliation(s)
- Anupriya Khare
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; and
| | - Krishnendu Chakraborty
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; and
| | - Mahesh Raundhal
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; and Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213
| | - Prabir Ray
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; and Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213
| | - Anuradha Ray
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213; and Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213
| |
Collapse
|
281
|
Aviles J, Bello A, Wong G, Fausther-Bovendo H, Qiu X, Kobinger G. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study. J Infect Dis 2015; 212 Suppl 2:S389-97. [DOI: 10.1093/infdis/jiv175] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
282
|
Wang T, Sun X, Zhao J, Zhang J, Zhu H, Li C, Gao N, Jia Y, Xu D, Huang FP, Li N, Lu L, Li ZG. Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood. Ann Rheum Dis 2015; 74:1293-301. [PMID: 24521740 DOI: 10.1136/annrheumdis-2013-204228] [Citation(s) in RCA: 78] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2013] [Accepted: 01/24/2014] [Indexed: 12/17/2022]
Abstract
OBJECTIVE Regulatory T cells (Tregs) with the plasticity of producing proinflammatory cytokine IL-17 have been demonstrated under normal and pathogenic conditions. However, it remains unclear whether IL-17-producing Tregs lose their suppressive functions because of their plasticity toward Th17 in autoimmunity. The aim of this study was to investigate IL-17-producing Tregs from patients with rheumatoid arthritis (RA), and characterise their regulatory capacity and clinical significance. METHODS Foxp3 and IL-17 coexpression were evaluated in CD4 T lymphocytes from RA patients. An in vitro T cell polarisation assay was performed to investigate the role of proinflammatory cytokines in IL-17-producing Treg polarisation. The suppressive function of IL-17-producing Tregs in RA was assessed by an in vitro suppression assay. The relationship between this Treg subset and clinical features in RA patients was analysed using Spearman's rank correlation test. RESULTS A higher frequency of IL-17-producing Tregs was present in the peripheral blood of RA patients compared with healthy subjects. These cells from peripheral blood showed phenotypic characteristics of Th17 and Treg cells, and suppressed T cell proliferation in vitro. Tregs in RA synovial fluid lost suppressive function. The Th17 plasticity of Tregs could be induced by IL-6 and IL-23. An increased ratio of this Treg subset was associated with decreased levels of inflammatory markers, including the erythrocyte sedimentation rate and C-reactive protein level, in patients with RA. CONCLUSIONS Increased levels of IL-17-producing Tregs were identified in RA patients. This Treg subset with Th17 plasticity in peripheral blood retained suppressive functions and was associated with milder inflammatory conditions, suggesting that this Treg population works as a negative regulator in RA, but in RA synovial site it may be pathogenic.
Collapse
Affiliation(s)
- Tian Wang
- Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People's Hospital, Beijing, China Department of Rheumatology & Immunology, Beijing An Zhen Hospital, Capital Medical University, Beijing, China
| | - Xiaolin Sun
- Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People's Hospital, Beijing, China
| | - Jing Zhao
- Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People's Hospital, Beijing, China
| | - Jing Zhang
- Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People's Hospital, Beijing, China
| | - Huaqun Zhu
- Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People's Hospital, Beijing, China
| | - Chun Li
- Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People's Hospital, Beijing, China
| | - Na Gao
- Department of Rheumatology & Immunology, Beijing An Zhen Hospital, Capital Medical University, Beijing, China
| | - Yuan Jia
- Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People's Hospital, Beijing, China
| | - Dakang Xu
- MIMR-PHI Institute of Medical Research, Monash University, Clayton, Victoria, Australia and Institute of Ageing Research, Hangzhou Normal University School of Medicine, Hangzhou, China
| | - Fang-Ping Huang
- Division of Immunology & Inflammation (Rheumatology Section), Department of Medicine, Imperial College Faculty of Medicine, Hammersmith Hospital, London, UK
| | - Ningli Li
- Shanghai Institute of Immunology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Liwei Lu
- Department of Pathology and Center of Infection and Immunology, The University of Hong Kong, Hong Kong, China
| | - Zhan-Guo Li
- Department of Rheumatology & Immunology, Clinical Immunology Center, Peking University People's Hospital, Beijing, China
| |
Collapse
|
283
|
Fuhrman CA, Yeh WI, Seay HR, Saikumar Lakshmi P, Chopra G, Zhang L, Perry DJ, McClymont SA, Yadav M, Lopez MC, Baker HV, Zhang Y, Li Y, Whitley M, von Schack D, Atkinson MA, Bluestone JA, Brusko TM. Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. THE JOURNAL OF IMMUNOLOGY 2015; 195:145-55. [PMID: 25994968 DOI: 10.4049/jimmunol.1402381] [Citation(s) in RCA: 178] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Accepted: 04/26/2015] [Indexed: 02/06/2023]
Abstract
Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4(+)FOXP3(+)Helios(+) thymic-derived Tregs and CD4(+)FOXP3(+)Helios(-) T cells, followed by comparison with CD4(+)FOXP3(-)Helios(-) T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4(+)CD25(+)CD127(lo/-) T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226(+)TIGIT(-) population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease.
Collapse
Affiliation(s)
- Christopher A Fuhrman
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610
| | - Wen-I Yeh
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610
| | - Howard R Seay
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610
| | - Priya Saikumar Lakshmi
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610
| | - Gaurav Chopra
- Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603
| | - Lin Zhang
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610
| | - Daniel J Perry
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610
| | - Stephanie A McClymont
- Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603
| | - Mahesh Yadav
- Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32603
| | - Maria-Cecilia Lopez
- Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco CA 94143
| | - Henry V Baker
- Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco CA 94143
| | - Ying Zhang
- Precision Medicine-Bioanalytical, Pfizer, Cambridge, MA 02139; and
| | - Yizheng Li
- Pfizer Research and Development Business Technologies, Cambridge, MA 02139
| | - Maryann Whitley
- Pfizer Research and Development Business Technologies, Cambridge, MA 02139
| | - David von Schack
- Precision Medicine-Bioanalytical, Pfizer, Cambridge, MA 02139; and
| | - Mark A Atkinson
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610
| | - Jeffrey A Bluestone
- Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco CA 94143
| | - Todd M Brusko
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610;
| |
Collapse
|
284
|
Bluestone JA, Bour-Jordan H, Cheng M, Anderson M. T cells in the control of organ-specific autoimmunity. J Clin Invest 2015; 125:2250-60. [PMID: 25985270 DOI: 10.1172/jci78089] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Immune tolerance is critical to the avoidance of unwarranted immune responses against self antigens. Multiple, non-redundant checkpoints are in place to prevent such potentially deleterious autoimmune responses while preserving immunity integral to the fight against foreign pathogens. Nevertheless, a large and growing segment of the population is developing autoimmune diseases. Deciphering cellular and molecular pathways of immune tolerance is an important goal, with the expectation that understanding these pathways will lead to new clinical advances in the treatment of these devastating diseases. The vast majority of autoimmune diseases develop as a consequence of complex mechanisms that depend on genetic, epigenetic, molecular, cellular, and environmental elements and result in alterations in many different checkpoints of tolerance and ultimately in the breakdown of immune tolerance. The manifestations of this breakdown are harmful inflammatory responses in peripheral tissues driven by innate immunity and self antigen-specific pathogenic T and B cells. T cells play a central role in the regulation and initiation of these responses. In this Review we summarize our current understanding of the mechanisms involved in these fundamental checkpoints, the pathways that are defective in autoimmune diseases, and the therapeutic strategies being developed with the goal of restoring immune tolerance.
Collapse
|
285
|
Nyirenda MH, Morandi E, Vinkemeier U, Constantin-Teodosiu D, Drinkwater S, Mee M, King L, Podda G, Zhang GX, Ghaemmaghami A, Constantinescu CS, Bar-Or A, Gran B. TLR2 Stimulation Regulates the Balance between Regulatory T Cell and Th17 Function: A Novel Mechanism of Reduced Regulatory T Cell Function in Multiple Sclerosis. THE JOURNAL OF IMMUNOLOGY 2015; 194:5761-74. [DOI: 10.4049/jimmunol.1400472] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2015] [Accepted: 04/19/2015] [Indexed: 01/19/2023]
|
286
|
Peripheral regulatory T lymphocytes recirculating to the thymus suppress the development of their precursors. Nat Immunol 2015; 16:628-34. [DOI: 10.1038/ni.3150] [Citation(s) in RCA: 120] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 03/17/2015] [Indexed: 12/14/2022]
|
287
|
Divergent effects of type-I interferons on regulatory T cells. Cytokine Growth Factor Rev 2015; 26:133-41. [DOI: 10.1016/j.cytogfr.2014.10.012] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Accepted: 10/22/2014] [Indexed: 02/07/2023]
|
288
|
Mari ER, Moore JN, Zhang GX, Rostami A. Mechanisms of immunological tolerance in central nervous system inflammatory demyelination. ACTA ACUST UNITED AC 2015; 6:264-274. [PMID: 26425145 DOI: 10.1111/cen3.12196] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Multiple sclerosis is a complex autoimmune disease of the central nervous system that results in a disruption of the balance between pro-inflammatory and anti-inflammatory signals in the immune system. Given that central nervous system inflammation can be suppressed by various immunological tolerance mechanisms, immune tolerance has become a focus of research in the attempt to induce long-lasting immune suppression of pathogenic T cells. Mechanisms underlying this tolerance induction include induction of regulatory T cell populations, anergy and the induction of tolerogenic antigen-presenting cells. The intravenous administration of encephalitogenic peptides has been shown to suppress experimental autoimmune encephalomyelitis and induce tolerance by promoting the generation of regulatory T cells and inducing apoptosis of pathogenic T cells. Safe and effective methods of inducing long-lasting immune tolerance are essential for the treatment of multiple sclerosis. By exploring tolerogenic mechanisms, new strategies can be devised to strengthen the regulatory, anti-inflammatory cell populations thereby weakening the pathogenic, pro-inflammatory cell populations.
Collapse
Affiliation(s)
- Elisabeth R Mari
- Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Jason N Moore
- Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Guang-Xian Zhang
- Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Abdolmohamad Rostami
- Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| |
Collapse
|
289
|
Nyilas R, Székely B, Váróczy L, Simon Z, Árokszállási A, Illés Á, Gergely L. Autoimmune haemolytic anaemia: a review and report of four cases. Orv Hetil 2015; 156:449-56. [DOI: 10.1556/oh.2015.30105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Treatment of autoimmune haemolytic anaemia is still a challenge to clinicians. Even today it may be lethal. Half of the cases are secondary due to an underlying disease, and the others are primary or idiopathic cases. According to the specificity and type of autoantibodies there are warm and cold type forms of autoimmune haemolytic anaemia. The hallmark of the diagnosis is to detect the presence of haemolysis by clinical and laboratory signs and detect the underlying autoantibodies. Treatment of autoimmune haemolytic anaemia is still a challenge to clinicians. We still loose patients due to excessive haemolysis or severe infections caused by immunosuppression. First line treatment is corticosteroids. Other immunosuppressive agents like: cyclophosphamide, azathioprine, cyclosporine or the off label rituximab can be used in case of corticosteroid refractoriness. Splenectomy is a considerable option in selective cases. The authors discuss treatment options and highlight difficulties by presenting 4 cases. Orv. Hetil., 2015, 156(11), 449–456.
Collapse
Affiliation(s)
- Renáta Nyilas
- Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Belgyógyászati Intézet, Hematológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
| | - Borbála Székely
- Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Belgyógyászati Intézet, Hematológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
| | - László Váróczy
- Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Belgyógyászati Intézet, Hematológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
| | - Zsófia Simon
- Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Belgyógyászati Intézet, Hematológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
| | - Anita Árokszállási
- Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Belgyógyászati Intézet, Hematológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
| | - Árpád Illés
- Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Belgyógyászati Intézet, Hematológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
| | - Lajos Gergely
- Debreceni Egyetem, Klinikai Központ, Általános Orvostudományi Kar Belgyógyászati Intézet, Hematológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
| |
Collapse
|
290
|
Hoeppli RE, Wu D, Cook L, Levings MK. The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome. Front Immunol 2015; 6:61. [PMID: 25741338 PMCID: PMC4332351 DOI: 10.3389/fimmu.2015.00061] [Citation(s) in RCA: 100] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 01/30/2015] [Indexed: 12/14/2022] Open
Abstract
Regulatory T cells (Tregs) are suppressive T cells that have an essential role in maintaining the balance between immune activation and tolerance. Their development, either in the thymus, periphery, or experimentally in vitro, and stability and function all depend on the right mix of environmental stimuli. This review focuses on the effects of cytokines, metabolites, and the microbiome on both human and mouse Treg biology. The role of cytokines secreted by innate and adaptive immune cells in directing Treg development and shaping their function is well established. New and emerging data suggest that metabolites, such as retinoic acid, and microbial products, such as short-chain fatty acids, also have a critical role in guiding the functional specialization of Tregs. Overall, the complex interaction between distinct environmental stimuli results in unique, and in some cases tissue-specific, tolerogenic environments. Understanding the conditions that favor Treg induction, accumulation, and function is critical to defining the pathophysiology of many immune-mediated diseases and to developing new therapeutic interventions.
Collapse
Affiliation(s)
- Romy E Hoeppli
- Department of Surgery, Child and Family Research Institute, University of British Columbia , Vancouver, BC , Canada
| | - Dan Wu
- Department of Surgery, Child and Family Research Institute, University of British Columbia , Vancouver, BC , Canada
| | - Laura Cook
- Department of Surgery, Child and Family Research Institute, University of British Columbia , Vancouver, BC , Canada
| | - Megan K Levings
- Department of Surgery, Child and Family Research Institute, University of British Columbia , Vancouver, BC , Canada
| |
Collapse
|
291
|
Olalekan SA, Cao Y, Hamel KM, Finnegan A. B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur J Immunol 2015; 45:988-98. [PMID: 25645456 DOI: 10.1002/eji.201445036] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2014] [Revised: 12/08/2014] [Accepted: 01/23/2015] [Indexed: 12/12/2022]
Abstract
Clinical efficacy in the treatment of rheumatoid arthritis with anti-CD20 (Rituximab)-mediated B-cell depletion has garnered interest in the mechanisms by which B cells contribute to autoimmunity. We have reported that B-cell depletion in a murine model of proteoglycan-induced arthritis (PGIA) leads to an increase in Treg cells that correlate with decreased autoreactivity. Here, we demonstrate that the increase in Treg cells after B-cell depletion is due to an increase in the differentiation of naïve CD4(+) T cells into Treg cells. Since the development of PGIA is dependent on IFN-γ and B cells are reported to produce IFN-γ, we hypothesized that B-cell-specific IFN-γ plays a role in the development of PGIA. Accordingly, mice with B-cell-specific IFN-γ deficiency were as resistant to the induction of PGIA as mice that were completely IFN-γ deficient. Importantly, despite a normal frequency of IFN-γ-producing CD4(+) T cells, B-cell-specific IFN-γ-deficient mice exhibited a higher percentage of Treg cells compared with that in WT mice. These data indicate that B-cell IFN-γ production inhibits Treg-cell differentiation and exacerbates arthritis. Thus, we have established that IFN-γ, specifically derived from B cells, uniquely contributes to the pathogenesis of autoimmunity through prevention of immunoregulatory mechanisms.
Collapse
Affiliation(s)
- Susan A Olalekan
- Department of Immunology/Microbiology, Rush University Medical Center, Cohn Research Building, Chicago, IL, USA
| | | | | | | |
Collapse
|
292
|
MacDonald KG, Dawson NAJ, Huang Q, Dunne JV, Levings MK, Broady R. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J Allergy Clin Immunol 2015; 135:946-955.e9. [PMID: 25678090 DOI: 10.1016/j.jaci.2014.12.1932] [Citation(s) in RCA: 113] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2014] [Revised: 11/14/2014] [Accepted: 12/11/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Systemic sclerosis (SSc) is an autoimmune disorder characterized by fibrosis of the skin and internal organs. Pathologic conversion of regulatory T (Treg) cells into inflammatory cytokine-producing cells is thought to be an important step in the progression of autoimmunity, but whether loss of normal Treg cell function contributes to SSc is unknown. OBJECTIVE We sought to determine whether Treg cells in the blood and skin of patients with SSc acquired abnormal production of effector cytokines. METHODS Peripheral blood and skin biopsy specimens were collected from control subjects and patients with limited or diffuse SSc. Flow cytometry was used to evaluate expression of cell-surface proteins and the cytokine production profile of forkhead box protein 3-positive Treg cells compared with forkhead box protein 3-negative conventional T cells. RESULTS Treg cells in the blood of patients with SSc had a normal phenotype and did not produce T-effector cytokines. In contrast, Treg cells from skin affected by SSc produced significant amounts of IL-4 and IL-13. Although Treg cells in the blood of patients with SSc did not make TH2 cytokines, they contained a significantly higher proportion of skin-homing cells expressing TH2 cell-associated chemokine receptors. Evidence that IL-33 caused the differentiation of skin Treg cells into TH2-like cells, combined with high tissue-localized expression of this cytokine in patients with SSc and expression of the ST2 chain of the IL-33 receptor on skin-localized Treg cells, suggests that IL-33 might be an important stimulator of tissue-localized loss of normal Treg cell function. CONCLUSION These data are the first evidence for the presence of TH2-like Treg cells in human autoimmunity and show that Treg cell plasticity can be tissue specific. Localized dysfunction of Treg cells is a previously unknown factor that might contribute to fibrosis in patients with SSc.
Collapse
MESH Headings
- Cytokines/metabolism
- Fibrosis
- Gene Expression
- Humans
- Interleukin-1 Receptor-Like 1 Protein
- Interleukin-13/metabolism
- Interleukin-13/pharmacology
- Lymphocyte Count
- Receptors, Cell Surface/genetics
- Receptors, Cell Surface/metabolism
- Receptors, Chemokine/metabolism
- Scleroderma, Systemic/genetics
- Scleroderma, Systemic/immunology
- Scleroderma, Systemic/metabolism
- Scleroderma, Systemic/pathology
- Skin/immunology
- Skin/metabolism
- Skin/pathology
- T-Lymphocyte Subsets/drug effects
- T-Lymphocyte Subsets/immunology
- T-Lymphocyte Subsets/metabolism
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/metabolism
Collapse
Affiliation(s)
- Katherine G MacDonald
- Department of Surgery, University of British Columbia, and the Child and Family Research Institute, Vancouver, British Columbia, Canada
| | - Nicholas A J Dawson
- Department of Surgery, University of British Columbia, and the Child and Family Research Institute, Vancouver, British Columbia, Canada
| | - Qing Huang
- Department of Medicine, University of British Columbia, and the Child and Family Research Institute, Vancouver, British Columbia, Canada
| | - James V Dunne
- Department of Medicine, University of British Columbia, and the Child and Family Research Institute, Vancouver, British Columbia, Canada; Department of Medicine, University of British Columbia, and St Paul's Hospital, Vancouver, British Columbia, Canada
| | - Megan K Levings
- Department of Surgery, University of British Columbia, and the Child and Family Research Institute, Vancouver, British Columbia, Canada
| | - Raewyn Broady
- Department of Medicine, University of British Columbia, and the Child and Family Research Institute, Vancouver, British Columbia, Canada.
| |
Collapse
|
293
|
Rossetti M, Spreafico R, Saidin S, Chua C, Moshref M, Leong JY, Tan YK, Thumboo J, van Loosdregt J, Albani S. Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2015; 194:113-24. [PMID: 25452562 PMCID: PMC4383769 DOI: 10.4049/jimmunol.1401145] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Regulatory T cell (Treg) therapy is a promising approach for transplant rejection and severe autoimmunity. Unfortunately, clinically meaningful Treg numbers can be obtained only upon in vitro culture. Functional stability of human expanded (e)Tregs and induced (i)Tregs has not been thoroughly addressed for all proposed protocols, hindering clinical translation. We undertook a systematic comparison of eTregs and iTregs to recommend the most suitable for clinical implementation, and then tested their effectiveness and feasibility in rheumatoid arthritis (RA). Regardless of the treatment, iTregs acquired suppressive function and FOXP3 expression, but lost them upon secondary restimulation in the absence of differentiation factors, which mimics in vivo reactivation. In contrast, eTregs expanded in the presence of rapamycin (rapa) retained their regulatory properties and FOXP3 demethylation upon restimulation with no stabilizing agent. FOXP3 demethylation predicted Treg functional stability upon secondary TCR engagement. Rapa eTregs suppressed conventional T cell proliferation via both surface (CTLA-4) and secreted (IL-10, TGF-β, and IL-35) mediators, similarly to ex vivo Tregs. Importantly, Treg expansion with rapa from RA patients produced functionally stable Tregs with yields comparable to healthy donors. Moreover, rapa eTregs from RA patients were resistant to suppression reversal by the proinflammatory cytokine TNF-α, and were more efficient in suppressing synovial conventional T cell proliferation compared with their ex vivo counterparts, suggesting that rapa improves both Treg function and stability. In conclusion, our data indicate Treg expansion with rapa as the protocol of choice for clinical application in rheumatological settings, with assessment of FOXP3 demethylation as a necessary quality control step.
Collapse
Affiliation(s)
- Maura Rossetti
- Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037; SingHealth Translational Immunology and Inflammation Centre, SingHealth, 169856 Singapore;
| | - Roberto Spreafico
- Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037; SingHealth Translational Immunology and Inflammation Centre, SingHealth, 169856 Singapore
| | - Suzan Saidin
- SingHealth Translational Immunology and Inflammation Centre, SingHealth, 169856 Singapore
| | - Camillus Chua
- SingHealth Translational Immunology and Inflammation Centre, SingHealth, 169856 Singapore
| | - Maryam Moshref
- Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Jing Yao Leong
- SingHealth Translational Immunology and Inflammation Centre, SingHealth, 169856 Singapore
| | - York Kiat Tan
- Department of Rheumatology and Immunology, Singapore General Hospital, 169608 Singapore; Duke-National University of Singapore Graduate Medical School, 169857 Singapore; and Yong Loo Lin School of Medicine, National University of Singapore, 117597 Singapore
| | - Julian Thumboo
- Department of Rheumatology and Immunology, Singapore General Hospital, 169608 Singapore; Duke-National University of Singapore Graduate Medical School, 169857 Singapore; and Yong Loo Lin School of Medicine, National University of Singapore, 117597 Singapore
| | - Jorg van Loosdregt
- Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Salvatore Albani
- Translational Research Unit, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037; SingHealth Translational Immunology and Inflammation Centre, SingHealth, 169856 Singapore; Duke-National University of Singapore Graduate Medical School, 169857 Singapore; and
| |
Collapse
|
294
|
Piconese S, Barnaba V. Stability of Regulatory T Cells Undermined or Endorsed by Different Type-1 Cytokines. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2015; 850:17-30. [DOI: 10.1007/978-3-319-15774-0_2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
295
|
Geginat J, Paroni M, Maglie S, Alfen JS, Kastirr I, Gruarin P, De Simone M, Pagani M, Abrignani S. Plasticity of human CD4 T cell subsets. Front Immunol 2014; 5:630. [PMID: 25566245 PMCID: PMC4267263 DOI: 10.3389/fimmu.2014.00630] [Citation(s) in RCA: 188] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Accepted: 11/25/2014] [Indexed: 12/23/2022] Open
Abstract
Human beings are exposed to a variety of different pathogens, which induce tailored immune responses and consequently generate highly diverse populations of pathogen-specific T cells. CD4(+) T cells have a central role in adaptive immunity, since they provide essential help for both cytotoxic T cell- and antibody-mediated responses. In addition, CD4(+) regulatory T cells are required to maintain self-tolerance and to inhibit immune responses that could damage the host. Initially, two subsets of CD4(+) helper T cells were identified that secrete characteristic effector cytokines and mediate responses against different types of pathogens, i.e., IFN-γ secreting Th1 cells that fight intracellular pathogens, and IL-4 producing Th2 cells that target extracellular parasites. It is now well established that this dichotomy is insufficient to describe the complexity of CD4(+) T cell differentiation, and in particular the human CD4 compartment contains a myriad of T cell subsets with characteristic capacities to produce cytokines and to home to involved tissues. Moreover, it has become increasingly clear that these T cell subsets are not all terminally differentiated cells, but that the majority is plastic and that in particular central memory T cells can acquire different properties and functions in secondary immune responses. In addition, there is compelling evidence that helper T cells can acquire regulatory functions upon chronic stimulation in inflamed tissues. The plasticity of antigen-experienced human T cell subsets is highly relevant for translational medicine, since it opens new perspectives for immune-modulatory therapies for chronic infections, autoimmune diseases, and cancer.
Collapse
Affiliation(s)
- Jens Geginat
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| | - Moira Paroni
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| | - Stefano Maglie
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| | - Johanna Sophie Alfen
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| | - Ilko Kastirr
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| | - Paola Gruarin
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| | - Marco De Simone
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| | - Massimiliano Pagani
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| | - Sergio Abrignani
- Fondazione Istituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi" INGM , Milan , Italy
| |
Collapse
|
296
|
Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol 2014; 45:344-55. [PMID: 25378177 DOI: 10.1002/eji.201344280] [Citation(s) in RCA: 165] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Revised: 10/01/2014] [Accepted: 10/31/2014] [Indexed: 11/10/2022]
Abstract
Systemic lupus erythematosus (SLE), an autoimmune disease, develops when immunologic self-tolerance fails. Treg cells are a subset of CD4(+) T cells that maintain self-tolerance by suppressing autoreactive lymphocytes. Defects in Treg cells are therefore considered to be an aspect of SLE pathogenesis. Nevertheless, reports on the numbers and function of Treg cells in SLE are contradictory and the definitive role of Treg cells in SLE remains unclear. In this review, we summarize findings from murine models and ex vivo experiments, which provide insights into the mechanisms that result in the breakdown of tolerance. We also include recent findings about Treg-cell subsets and their markers in human SLE. The identification of unique markers to identify bona fide Treg cells, as well as therapies to reconstitute the balance between Treg cells and autoreactive T cells in SLE, are the future challenges for SLE research.
Collapse
Affiliation(s)
- Kim Ohl
- Department of Pediatrics, Medical Faculty, RWTH Aachen, Aachen, Germany; IZKF Aachen, Medical Faculty, RWTH Aachen, Aachen, Germany
| | | |
Collapse
|
297
|
Pesenacker AM, Broady R, Levings MK. Control of tissue-localized immune responses by human regulatory T cells. Eur J Immunol 2014; 45:333-43. [PMID: 25378065 DOI: 10.1002/eji.201344205] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Revised: 09/30/2014] [Accepted: 10/31/2014] [Indexed: 12/25/2022]
Abstract
Treg cells control immune responses to self and nonharmful foreign antigens. Emerging data from animal models indicate that Treg cells function in both secondary lymphoid organs and tissues, and that these different microenvironments may contain specialized subsets of Treg cells with distinct mechanisms of action. The design of therapies for the restoration of tissue-localized immune homeostasis is dependent upon understanding how local immune responses are influenced by Treg cells in health versus disease. Here we review the current state of knowledge about human Treg cells in four locations: the skin, lung, intestine, and joint. Despite the distinct biology of these tissues, there are commonalities in the biology of their resident Treg cells, including phenotypic and functional differences from circulating Treg cells, and the presence of cytokine-producing (e.g. IL-17(+)) FOXP3(+) cells. We also highlight the challenges to studying tissue Treg cells in humans, and opportunities to use new technologies for the detailed analysis of Treg cells at the single-cell level. As emerging biological therapies are increasingly targeted toward tissue-specific effects, it is critical to understand their potential impact on local immune regulation.
Collapse
Affiliation(s)
- Anne M Pesenacker
- Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada; Child & Family Research Institute, Vancouver, British Columbia, Canada
| | | | | |
Collapse
|
298
|
Ehrlich A, Castilho TM, Goldsmith-Pestana K, Chae WJ, Bothwell ALM, Sparwasser T, McMahon-Pratt D. The immunotherapeutic role of regulatory T cells in Leishmania (Viannia) panamensis infection. THE JOURNAL OF IMMUNOLOGY 2014; 193:2961-70. [PMID: 25098291 DOI: 10.4049/jimmunol.1400728] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Leishmania (Viannia) parasites are etiological agents of cutaneous leishmaniasis in the New World. Infection is characterized by a mixed Th1/Th2 inflammatory response, which contributes to disease pathology. However, the role of regulatory T cells (Tregs) in Leishmania (Viannia) disease pathogenesis is unclear. Using the mouse model of chronic L. (V.) panamensis infection, we examined the hypothesis that Treg functionality contributes to control of pathogenesis. Upon infection, Tregs (CD4(+)Foxp3(+)) presented with a dysregulated phenotype, in that they produced IFN-γ, expressed Tbet, and had a reduced ability to suppress T cell proliferation in vitro. Targeted ablation of Tregs resulted in enlarged lesions, increased parasite load, and enhanced production of IL-17 and IFN-γ, with no change in IL-10 and IL-13 levels. This indicated that an increased inflammatory response was commensurate with disease exacerbation and that the remaining impaired Tregs were important in regulation of disease pathology. Conversely, adoptive transfer of Tregs from naive mice halted disease progression, lowered parasite burden, and reduced cytokine production (IL-10, IL-13, IL-17, IFN-γ). Because Tregs appeared to be important for controlling infection, we hypothesized that their expansion could be used as an immunotherapeutic treatment approach. As a proof of principle, chronically infected mice were treated with rIL-2/anti-IL-2 Ab complex to expand Tregs. Treatment transitorily increased the numbers and percentage of Tregs (draining lymph node, spleen), which resulted in reduced cytokine responses, ameliorated lesions, and reduced parasite load (10(5)-fold). Thus, immunotherapy targeting Tregs could provide an alternate treatment strategy for leishmaniasis caused by Leishmania (Viannia) parasites.
Collapse
Affiliation(s)
- Allison Ehrlich
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520
| | - Tiago Moreno Castilho
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520
| | - Karen Goldsmith-Pestana
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520
| | - Wook-Jin Chae
- Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520; and
| | - Alfred L M Bothwell
- Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520; and
| | - Tim Sparwasser
- Institute of Infection Immunology, Centre for Experimental and Clinical Infection Research, TWINCORE, 30625 Hanover, Germany
| | - Diane McMahon-Pratt
- Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06520;
| |
Collapse
|
299
|
Tilahun AY, Chowdhary VR, David CS, Rajagopalan G. Systemic inflammatory response elicited by superantigen destabilizes T regulatory cells, rendering them ineffective during toxic shock syndrome. THE JOURNAL OF IMMUNOLOGY 2014; 193:2919-30. [PMID: 25092888 DOI: 10.4049/jimmunol.1400980] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Life-threatening infections caused by Staphylococcus aureus, particularly the community-acquired methicillin-resistant strains of S. aureus, continue to pose serious problems. Greater virulence and increased pathogenicity of certain S. aureus strains are attributed to higher prevalence of exotoxins. Of these exotoxins, the superantigens (SAg) are likely most pathogenic because of their ability to rapidly and robustly activate the T cells even in extremely small quantities. Therefore, countering SAg-mediated T cell activation using T regulatory cells (Tregs) might be beneficial in diseases such as toxic shock syndrome (TSS). As the normal numbers of endogenous Tregs in a typical host are insufficient, we hypothesized that increasing the Treg numbers by administration of IL-2/anti-IL-2 Ab immune complexes (IL2C) or by adoptive transfer of ex vivo expanded Tregs might be more effective in countering SAg-mediated immune activation. HLA-DR3 transgenic mice that closely recapitulate human TSS were treated with IL2C to increase endogenous Tregs or received ex vivo expanded Tregs. Subsequently, they were challenged with SAg to induce TSS. Analyses of various parameters reflective of TSS (serum cytokine/chemokine levels, multiple organ pathology, and SAg-induced peripheral T cell expansion) indicated that increasing the Tregs failed to mitigate TSS. On the contrary, serum IFN-γ levels were increased in IL2C-treated mice. Exploration into the reasons behind the lack of protective effect of Tregs revealed IL-17 and IFN-γ-dependent loss of Tregs during TSS. In addition, significant upregulation of glucocorticoid-induced TNFR family-related receptor on conventional T cells during TSS could render them resistant to Treg-mediated suppression, contributing to failure of Treg-mediated immune regulation.
Collapse
Affiliation(s)
| | - Vaidehi R Chowdhary
- Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN 55905; and
| | - Chella S David
- Department of Immunology, Mayo Clinic, Rochester, MN 55905
| | - Govindarajan Rajagopalan
- Department of Immunology, Mayo Clinic, Rochester, MN 55905; Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905
| |
Collapse
|
300
|
Araya N, Sato T, Ando H, Tomaru U, Yoshida M, Coler-Reilly A, Yagishita N, Yamauchi J, Hasegawa A, Kannagi M, Hasegawa Y, Takahashi K, Kunitomo Y, Tanaka Y, Nakajima T, Nishioka K, Utsunomiya A, Jacobson S, Yamano Y. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Invest 2014; 124:3431-42. [PMID: 24960164 PMCID: PMC4109535 DOI: 10.1172/jci75250] [Citation(s) in RCA: 74] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2014] [Accepted: 05/08/2014] [Indexed: 12/14/2022] Open
Abstract
Human T-lymphotropic virus type 1 (HTLV-1) is linked to multiple diseases, including the neuroinflammatory disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T cell leukemia/lymphoma. Evidence suggests that HTLV-1, via the viral protein Tax, exploits CD4+ T cell plasticity and induces transcriptional changes in infected T cells that cause suppressive CD4+CD25+CCR4+ Tregs to lose expression of the transcription factor FOXP3 and produce IFN-γ, thus promoting inflammation. We hypothesized that transformation of HTLV-1-infected CCR4+ T cells into Th1-like cells plays a key role in the pathogenesis of HAM/TSP. Here, using patient cells and cell lines, we demonstrated that Tax, in cooperation with specificity protein 1 (Sp1), boosts expression of the Th1 master regulator T box transcription factor (T-bet) and consequently promotes production of IFN-γ. Evaluation of CSF and spinal cord lesions of HAM/TSP patients revealed the presence of abundant CD4+CCR4+ T cells that coexpressed the Th1 marker CXCR3 and produced T-bet and IFN-γ. Finally, treatment of isolated PBMCs and CNS cells from HAM/TSP patients with an antibody that targets CCR4+ T cells and induces cytotoxicity in these cells reduced both viral load and IFN-γ production, which suggests that targeting CCR4+ T cells may be a viable treatment option for HAM/TSP.
Collapse
MESH Headings
- Adult
- Aged
- Antibodies, Monoclonal/therapeutic use
- CD4-Positive T-Lymphocytes/immunology
- CD4-Positive T-Lymphocytes/virology
- Cell Line
- Cytotoxicity, Immunologic
- Female
- Gene Products, tax/immunology
- Human T-lymphotropic virus 1/immunology
- Human T-lymphotropic virus 1/pathogenicity
- Humans
- Immunotherapy
- Interferon-gamma/biosynthesis
- Interferon-gamma/genetics
- Male
- Middle Aged
- Paraparesis, Tropical Spastic/genetics
- Paraparesis, Tropical Spastic/immunology
- Paraparesis, Tropical Spastic/virology
- Receptors, CCR4/antagonists & inhibitors
- Receptors, CCR4/immunology
- Receptors, CCR4/metabolism
- Sp1 Transcription Factor/immunology
- T-Box Domain Proteins/genetics
- T-Box Domain Proteins/immunology
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/virology
- Th1 Cells/immunology
- Th1 Cells/virology
- Viral Load/immunology
Collapse
Affiliation(s)
- Natsumi Araya
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Tomoo Sato
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Hitoshi Ando
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Utano Tomaru
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Mari Yoshida
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Ariella Coler-Reilly
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Naoko Yagishita
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Junji Yamauchi
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Atsuhiko Hasegawa
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Mari Kannagi
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Yasuhiro Hasegawa
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Katsunori Takahashi
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Yasuo Kunitomo
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Yuetsu Tanaka
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Toshihiro Nakajima
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Kusuki Nishioka
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Atae Utsunomiya
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Steven Jacobson
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| | - Yoshihisa Yamano
- Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Pathology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan. Department of Immunotherapeutics, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan. Department of Neurology, St. Marianna University School of Medicine, Kanagawa, Japan. Department of Immunology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Institute of Medical Science and Center for Clinical Research, Tokyo Medical University, Tokyo, Japan. Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan. Viral Immunology Section, Neuroimmunology Branch, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|